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Background: Anti-signal recognition particle (SRP) antibodies are used as serological markers of necrotizing
myopathy, which is characterized by many necrotic and regenerative muscle fibers without or with minimal
inflammatory cell infiltration. The clinical spectrum associated with anti-SRP antibodies seems to be broad.
Objective: To describe the clinical characteristics, autoantibodies status, and neurological outcome associated with
anti-SRP antibody.
Methods: We studied clinical and laboratory findings of 100 patients with inflammatory myopathy and anti-SRP
antibodies. Anti-SRP antibodies in serum were detected by the presence of 7S RNA using RNA immunoprecipitation.
In addition, enzyme-linked immunosorbent assays (ELISAs) using a 54-kD protein of SRP (SRP54) and 3-hydroxyl-3-
methylglutatyl-coenzyme A reductase (HMGCR) were also conducted.
Results: The mean onset age of the 61 female and 39 male patients was 51 years (range 4–82 years); duration ≥
12 months before diagnosis was seen in 23 cases. All patients presented limbs weakness; 63 had severe weakness,
70 neck weakness, 41 dysphagia, and 66 muscle atrophy. Extramuscular symptoms and associated disorders were
infrequent. Creatine kinase levels were mostly more than 1000 IU/L. Histological diagnosis showed 84 patients
had necrotizing myopathy, and apparent cell infiltration was observed in 16 patients. Anti-SRP54 antibodies were
undetectable in 18 serum samples with autoantibodies to 7S RNA. Anti-HMGCR antibodies were positive in 3 patients
without the statin treatment, however, were negative in 5 patients with statin-exposure at disease onset. All but 3
patients were treated by corticosteroids and 62 (77 %) of these 81 patients required additional immunotherapy.
After 2-years treatment, 22 (27 %) of these 81 patients had poor neurological outcomes with modified Rankin scale
scores of 3–5. Multivariate analysis revealed that pediatric disease onset was associated with the poor outcomes.
Conclusion: Anti-SRP antibodies are associated with different clinical courses and histological presentations.
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Signal recognition particle (SRP), which is a ubiquitous
cytoplasmic RNA protein consisting of 7S RNA and 6
proteins with molecular weights of 9, 14, 19, 54, 68 and
72 kD, mediates the translocation of newly synthesized
protein across the endoplasmic reticulum. Anti-SRP
antibodies were first discovered in the serum of patients
with clinical polymyositis by the presence of 7S RNA
detected by RNA immunoprecipitation [1–3]. RNA im-
munoprecipitation is a powerful method for the detec-
tion of various autoantibodies, including those against
aminoacyl transfer RNA synthetase (ARS). There is an-
other method for detecting anti-SRP antibodies: an
immunoassay using a 54-kD subunit protein of SRP
(SRP54) as the antigen [4]. Immunoassays using SRP54
such as enzyme-linked immunosorbent assays (ELISAs)
are easily performed and have the advantage of allowing
the screening of many serum samples. However, com-
parisons of the RNA immunoprecipitation method and the
SRP54 immunoassay method have not been conducted.
Based on an accumulation of clinical observations, it
was reported that anti-SRP antibodies are associated
with the severe and refractory myositis and that they
can be regarded as myositis-specific antibodies [1].
Histological diagnoses have confirmed a tight association
between anti-SRP antibodies and immune-mediated nec-
rotizing myopathy [5–8]. Anti-SRP antibodies are now
used as serological markers of necrotizing myopathy,
which is characterized by many necrotic and regenera-
tive muscle fibers without or with minimal inflammatory
cell infiltration. Since there is a lack of information re-
garding the inflammatory processes in muscle histology,
the detection of anti-SRP antibodies merely suggests an
immune-mediated mechanism. The clinical spectrum
associated with anti-SRP antibodies seems to be broad
[9–12]. We hypothesized that anti-SRP antibodies could
define a distinct subset of inflammatory myopathies, and
the purpose of present study is to report the clinical
characteristics, autoantibody status, and neurological




From 1997 to 2012, we followed 17 patients with inflam-
matory myopathy with anti-SRP antibody at Keio Univer-
sity Hospital. Between January 2008 and September 2012,
we identified another 83 patients with anti-SRP antibodies
who were referred from all over Japan to Keio University
Hospital or the National Center of Neurology and
Psychiatry. Anti-SRP antibodies were detected by RNA
immunoprecipitation. The diagnosis of inflammatory
myopathy was based on the histological diagnosis with
clinical, electrophysiological, and radiological findings.Clinical information was retrospectively obtained by the
authors or provided by referring physicians. This study
was approved by the Institutional Review Boards at Keio
University and the National Center of Neurology and
Psychiatry.
Histology
Necrotizing myopathy was diagnosed based on the
observation of many necrotic fibers as the predominant
abnormal histological feature without or with minimal
inflammatory cell infiltration [7, 8]. Sporadic inclusion
body myositis was diagnosed by the identification of
rimmed vacuoles with non-necrotic fibers invaded by
mononuclear cells or increased major histocompatibility
complex (MHC) class I expression. Polymyositis was
diagnosed based on endomysial inflammation cell infil-
trate surrounding or invading non-necrotic muscle fibers
accompanied by ubiquitous MHC class I expression.
Dermatomyositis was diagnosed by the identification of
the presence of perifascicular atrophy [13, 14]. Other
inflammatory myopathies were regarded as non-specific
myositis including perimysial or endomysial inflamma-
tory cell infiltration.
RNA immunoprecipitation
Ten-μl of serum was mixed with 2 mg of protein A-
Sepharose CL-4B (Pharmacia Biotech AB) in 500 μl of im-
munoprecipitation buffer and incubated for 2 h. After
washing 3 times with immunoprecipitation buffer, antigen-
bound Sepharose beads were mixed with 100 μl of HeLa
cell extract (6 × 10 cell equivalents per sample) for 2 h, and
then 30 μl of 3 M sodium acetate, 30 μl of 10 % sodium
dodecyl sulfate, and 300 μl of phenol:chloroform:isoamyl
alcohol (50:50:1, containing 0.1 % 8-hydroxyquinoline)
were added to extract the bound RNA. After ethanol
precipitation, the RNA was resolved by using a 7 M
urea-8 % polyacrylamide gel, and the gel was silver-
stained (Bio-Rad). Immunoprecipitated RNA located in the
7S RNA lesion was regarded as anti-SRP antibody (Fig. 1).
ELISA
First, 96-well polyvinyl plates (Sumitomo Bakelite) were
coated with recombinant SRP54 protein (Diarect) at
1 μg/ml diluted in phosphate buffered saline. The
remaining blocking sites were blocked with 3 % bovine
serum albumin. The wells were incubated with serum
samples diluted 1:200 and subsequently with peroxidase-
conjugated anti-human IgG (Jackson Immuno Research)
diluted 1:100,000. The antibody binding was visualized
by incubation with tetramethylbenzidine (1 mg/ml) in
phosphate-citrate buffer. The reaction was stopped by
1 M sulfuric acid. The optical density at 450 nm
(OD450) was read with an automatic plate reader
(Biorad). Samples were tested in duplicate. In addition,
Fig. 1 RNA immunoprecipitation assay. Urea and 8 % PAGE of
phenol-extracted immunoprecipitation from HeLa cell extracts were
developed with silver staining. Total RNA indicates 7S RNA and transfer
RNA regions. The serum samples #2 and #6 contained anti-signal
recognition particle (SRP) antibodies. In contrast, one of autoanti-
bodies against aminoacyl transfer RNA synthetase, anti-PL-7 antibody
(anti-threonyl-tRNA synthetase) was found in serum #5
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reductase (HMGCR) were measured using an ELISA based
on the original method with some modifications [15].We also used sera from 46 myositis patients without
autoantibodies, 46 patients with myasthenia gravis, 40
patients with Duchenne muscular dystrophy, and 40
normal healthy volunteers as controls.
Statistical analyses
Statistical analyses were performed using JMP version 9




The clinical features of the total 100 patients with anti-
SRP antibodies are summarized in Table 1. There were
61 female, 39 males. The mean age of disease onset was
51.3 ± 19.3 years (range 4–82 years). The patients’ ages
at disease onset were distributed widely, and peaked in
the 60s (Fig. 2). Pediatric disease onset at age ≤ 16 years
was found in 8 patients.
Initial presentation
Antecedent infection was found in 7 patients. Statins
were administered in 5 patients at disease onset. Inflam-
matory myopathy developed in 4 patients during the
follow-up of another rheumatic disease. The durations
of disease progression varied. The duration from the dis-
ease onset to the first examination was within 12 months
in 77 patients, and ≥ 12 months in the other 23 patients.
With regard to the initial symptoms, weakness in the
legs, such as difficulty in working or climbing stairs, was
observed in 67 patients. Weakness in the arms was the
initial symptom in 19 patients. The 7 patients with bulbar
symptoms all suffered from difficulties in swallowing, but
not in speaking. Among trunk muscles, neck weakness
and muscle atrophy in the scapular muscles were reported
in 5 and 2 patients, respectively.
Clinical features
All patients had limb weakness. The distribution of
weakness was proximal-dominant and symmetrical, and
affected legs more than arms. Severe limbs weakness
with the grade ≤ 3/5 assessed by manual muscle strength
(Medical Research Council scale grade) was observed in
63 patients. Laterality of limb weakness was seen in 16
patients.
Seventy patients experienced neck weakness. Among
them, dropped head was observed in 7 patients. Dyspha-
gia was observed in 41 patients, and nasogastric tubes
were necessary in 5 patients. Facial and cardiac muscle
involvement was infrequent. The vital capacity percent-
age in the respiratory function test was decreased in 12
patients, 2 of whom needed mechanical ventilation.
Neurological examinations revealed muscle atrophy in
66 patients: among them, scapular winging was seen in
Table 1 Characteristics of the 100 patients with
inflammatory myopathy with anti-SRP antibody
Findings (n)
Females/males 61/39
Age at diseases onset
Mean ± SD 51.3 ± 19.3
Age ≤ 15 years 8
Antecedent infection 7
Statin-exposure 5









Legs predominantly than arms 69
Severe limbs weakness 63
Laterality 16
Distal muscle dominant 3
Neck weakness 70
Dysphagia 41
Facial muscle involvement 10
Cardiac muscle involvement 2
Decreased capacity of respiratory function 12
Muscle atrophy 66
Scapular winging 10












Creatine kinase (IU/L, mean ± SD) 6161 ± 4725
Elevated C-reactive protein 17
Antinuclear antibody positivity 5
Electromyography
Spontaneous activity 41/86 (48 %)
Table 1 Characteristics of the 100 patients with
inflammatory myopathy with anti-SRP antibody
(Continued)
Low-amplitude, short-duration motor unit potentials 79/86 (92 %)
Muscle images
Atrophy on CT or MRI 46/79 (58 %)
Increased signals on T2 or STIR images 49/58 (84 %)
Histological diagnosis
Necrotizing myopathy 84





7S RNA of SRP 100
54-kD protein of SRP 82
3-hydroxyl-3-methylglutatyl-coenzyme A reductase 3
Aminoacyl transfer RNA synthetase 0
SRP, signal recognition particle; STIR, short T1 inversion recovery
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diagnosis of facioscapulohumeral muscular dystrophy.
Deep tendon reflexes were decreased or absent in 51 pa-
tients. Thirty-four patients reported Myalgia, especially
in the early stage of disease.
With regard to extramuscular manifestations, the fre-
quencies of fever, skin rash, arthritis, and Raynaud
phenomenon were generally low. Chest CT revealed
interstitial lung disease in 13 patients, all of whom had
non-specific interstitial fibrosis, and their respiratory
symptoms were generally mild. Malignancy (including
lung, breast, stomach, ovarian and renal cancers) was dis-
covered in 5 patients. Concomitant rheumatic diseasesFig. 2 Distribution of onset ages in the 100 patients with inflammatory
myopathy with anti- SRP antibody
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erythematosus in 2, and rheumatic arthritis in 2 patients.
Laboratory, electrophysiological, and radiological tests
With regard to the routine laboratory findings, serum
creatine kinase levels were markedly elevated to more than
1000 IU/L in all but 2 patients (mean 6161 IU/L, range
735–21,544 IU/L). In addition, the median on peaked cre-
atine kinase level was 4998 IU/L (25–75 % interquartile
range 3354–7464 IU/L). Elevation in C-reactive protein
(≥1 mg/dL) was seen in 17 patients. Positivity of antinu-
clear antibody (≥1:160) was detected in only 5 patients.
We assessed the findings of electromyography from 86
patients. Needle electromyography revealed positive
sharp waves and/or fibrillation potentials in 41 (48 %) of
the 86 patients. Patients with chronic progression tended
to lack the spontaneous activity. In contrast, myopathic
motor unit potentials such as short-duration and low-
amplitude motor units with early recruitment were
detected in 92 % of the 86 patients.
Information obtained by muscle CT or MRI was avail-
able for 38 and 58 patients, respectively. The distribution
of inflammation and muscle atrophy was detectable in
muscle CT or MRI in the thighs (Fig. 3). Muscle atrophy
on CT or MRI was seen in 46 (58 %) of 79 patients. High-
intensity signal in T2 or short TI inversion recovery
(STIR) images were observed in 49 (84 %) of 58 patients.
Histological diagnosis
With regard to the histological diagnoses, 84 patients
had necrotizing myopathy, in which necrotic fibers > 1 %
of total muscle fibers accompanied by regeneration
fibers were observed. In contrast, there was apparent
inflammatory cell infiltration in 16 patients. Inflamma-
tory cell infiltration was regarded as positive when it was
seen in the endomysial or perimysial regions, but not in
the vicinity of necrotic fibers. Areas of invaded cellsFig. 3 Muscle images of thighs in patients with anti-SRP antibodies. (a) Mu
images. (c) Increased signals on MRI STIR images (upper) and muscle atropwere in the endomysial region (n = 5), perimysial region
(n = 7), or both (n = 4). The histological diagnoses of
sporadic inclusion body myositis, polymyositis and derm-
atomyositis were made in 0, 1, and 1 patient, respectively.
The other 14 patients had non-specific myositis.
Detection of autoantibodies
All 100 serum samples were positive for anti-SRP anti-
bodies using RNA immunoprecipitation. RNA immuno-
precipitation revealed additional autoantibodies including
anti-Ro/SS-A or anti-La/SS-B in 11, anti-U1RNP in 4,
anti-Ku in 1, anti-Th/To in 1, and anti-ribosome in 1
serum sample. It was noted that no serum contained anti-
ARS antibodies.
In addition to the gold standard detection method,
anti-SRP antibodies were also evaluated by an ELISA
using recombinant SRP54 protein as an antigen. The
anti-SRP54 antibody index was calculated as the OD450
of the samples divided by the OD450 of the referential
serum. A total of 272 serum samples were examined
(Fig. 4). When the cut-off value was set as the mean + 5 ×
the SD of the healthy control sera (anti-SRP54 antibody
index: 0.37), positivity for the anti-SRP54 antibody was
detected in 82 serum samples with anti-SRP antibodies
detected by RNA immunoprecipitation. The disease
control samples (including those with myositis, myas-
thenia gravis and Duchenne muscular dystrophy) were
all negative for anti-SRP54 antibody. Importantly, 18
serum samples had autoantibody against 7S RNA of
SRP, but not against SRP54 protein.
We evaluated the serial changes in anti-SRP54 antibody
index in ten serum samples. The anti-SRP54 antibody
index decreased from pre-treatment to post-treatment
(Fig. 4b). Since the longitudinal follow-up was not enough,
we could not determine the association between the serial
change of anti-SRP54 antibody index and creatine kinase
or muscle weakness. In contrast, we evaluated the peakedscle atrophy on MRI T1 images. (b) High signal intensity on MRI STIR
hy in CT (lower)
Fig. 4 SRP54 enzyme-linked immunosorbent assay (ELISA). (a) Antibodies reactive with recombinant SRP54 protein by ELISA in sera from patients
with anti-7S RNA positive myopathy, myositis without autoantibodies, myasthenia gravis, muscular dystrophy, and healthy controls. The cut-off
level for positivity of anti-SRP54 antibody index is indicated by the broken line. (b) Serial changes of anti-SRP54 antibody index between pre- and
post-treatment in 10 patients with anti-SRP antibodies. (c) Correlation of anti-SRP54 antibody index determined by ELISA and serum creatine kinase in
100 patients with anti-SRP antibodies
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body index using same blood sample. There was no cor-
relation between creatine kinase and anti-SRP54 antibody
index in the 100 serum samples (r = 0.003, Fig. 4c).
To exclude the possibility of statin-induced myopathy,
we also measured anti-HMGCR antibodies in the 100
serum samples. Anti-HMGCR antibodies were negative
in the 5 patients with statin-exposure. Although anti-
HMGCR antibodies were detected in 3 patients without
the statin treatment, the titers of anti-HMGCR anti-
bodies were much lower than those of the patients with
statin-induced myopathy [15].Treatment
We further evaluated the clinical course of the 84 pa-
tients followed over 2 years. All but 3 of the 84 patients
were treated with oral prednisolone. Two patients were
proven to be positive for anti-SRP antibodies ten year
after the disease onset. They suffered from the progres-
sion of muscle weakness during the first 3–5 years, and
then the disease activity stopped. The remaining patient
developed a cerebral infarction soon after undergoing
the muscle biopsy.
In addition to prednisolone, 62 (77 %) of 81 patients re-
quired additional immunotherapy, including intravenous
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prednisolone plus therapy (n = 32), tacrolimus (n = 22),
methotrexate (n = 11), azathioprine (n = 11), cyclosporine
(n = 9), intravenous cyclophosphamide (n = 3), or plasma
exchange (n = 3).
Clinical course
There were 3 types of clinical courses. In the first type,
26 (32 %) of 81patients responded well to immunother-
apy without neurological deficits, although they required
2–3 months to respond to treatment. In the second type,
45 patients (56 %) were refractory to various immuno-
therapy regimens. The immunotherapy resulted in a de-
crease of the patients’ creatine kinase levels, but the
recovery of muscle weakness was incomplete. These pa-
tients required long-term immunotherapy and suffered
from side effects. Finally, the remaining ten (12 %) pa-
tients showed progressive muscle weakness. Their re-
sponse to immunotherapy was minimal.
Neurological outcome
The patients’ neurological outcomes were assessed at
2 years after the initiation of immunotherapy using
modified Rankin Scale. Of the 81 patients treated with
immunotherapy, 22 (27 %) had difficulties in their daily
living graded as modified Rankin Scale scores 3–5. We
divided these 81 patients into 2 groups: those with a
good outcome, defined as a modified Rankin Scale score
of 0–2 (n = 59) and those with a poor outcome, defined
as a modified Rankin Scale of 3–5 (n = 22). WeTable 2 Comparison of clinical features of 81 patients with go
Good outcome
(n = 59)
Females 35 (59 %)
Age at disease onset≤ 15 years 1 (2 %)
Disease progression > 12 months 12 (20 %)
Clinical characteristics
Legs predominantly than arms 43 (73 %)
Severe limbs weakness 31 (53 %)
Neck weakness 37 (63 %)
Dysphagia 20 (34 %)
Muscle atrophy 32 (54 %)
Decreased deep tendon reflex 28 (47 %)
Myalgia 19 (32 %)
Interstitial lung disease 12 (20 %)
Laboratory findings
Creatine kinase (IU/L) 6181 ± 4313
Elevated C-reactive protein 7 (12 %)
Anti-SRP54 antibody index 1.4 ± 1.0
Lymphocyte infiltration in histology 11 (19 %)compared the clinical features before immunotherapy
between the 2 groups (Table 2).
We found that pediatric disease onset, severe limb
weakness, dysphagia, muscle atrophy, absence of inter-
stitial lung disease, and elevated C-reactive protein were
associated with the poor outcome. Moreover, multivari-
ate logistic analyses revealed that pediatric disease onset
was the only independent factor associated with the
poor outcome (p = 0.003, odds ratio: 28.4, 95 % confi-
dential interval 2.82–845).
Based on the result of multivariate logistic analyses,
the onset age was an important factor for anti-SRP my-
opathy. We compared clinical and laboratory character-
istics between 13 patients with younger onset and 68
patients with older onset using the cutoff age of 30 years
(Additional file 1). The younger onset was associated
with chronic disease progression, severe limbs and neck
weakness and muscle atrophy. The neurological out-
come was more severe in the younger onset compared
with the older onset.
Cause of death
Among 17 patients followed at Keio University Hospital
for a longer follow-up, 7 patients died during the clinical
course (age 74 ± 11 years). The side effects of the long-
term use of corticosteroids may have been responsible
for the death of 5 patients (cerebral infarction in 2
patients, ischemic heart diseases in 2, and bacterial
pneumonia in 1 patient). The remaining 2 patients died
of lung cancer and intestinal lung disease, respectively.od or poor outcomes
Poor outcome p
(n = 22)
16 (73 %) 0.3
6 (27 %) 0.0003
8 (36 %) 0.1
16 (73 %) 1.0
20 (91 %) 0.001
17 (77 %) 0.2
14 (63 %) 0.02
20 (91 %) 0.002
15 (68 %) 0.1
7 (32 %) 1.0
0 (0 %) 0.02
7079 ± 5263 0.5
8 (36 %) 0.01
1.3 ± 1.1 0.8
3 (14 %) 0.6
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The present case series of 100 patients with inflamma-
tory myopathy with anti-SRP antibody provided the fol-
lowing findings: (i) patients of all ages were affected; (ii)
neurological symptoms were characterized by severe limb,
trunk, and bulbar muscle weakness with atrophy; (iii)
histological diagnoses showed 84 patients had necrotizing
myopathy; (iv) anti-SRP54 antibodies were undetectable in
18 serum samples containing autoantibodies to 7S RNA of
SRP; and (v) pediatric disease onset was associated with
the poor neurological outcome. Taken together, these
results led us to conclude that anti-SRP antibodies can be
used determine a distinct subset in inflammatory myop-
athy (anti-SRP myopathy).
The diagnosis of anti-SRP myopathy is based on both
the detection of anti-SRP antibodies in patients’ serum
and the histological diagnosis of inflammatory myop-
athy, usually necrotizing myopathy. Ancillary tests and
results including markedly elevated serum creatine
kinase, electromyography, and muscle images support
the diagnosis. Since the disease presentation and pro-
gression are variable, the clinical diagnosis is sometimes
difficult. The chronic progression of anti-SRP myopathy
accompanied by younger onset, severe muscle weakness
and atrophy mimics muscular dystrophy. When a pa-
tient’s muscle weakness appears to be progressing faster
than expected, as in muscular dystrophy, it may be
worth testing for anti-SRP antibodies. The broad clinical
presentation of SRP autoimmunity requires an expanded
consideration of the anti-SRP antibody detection test in
patients of all ages.
Necrotizing myopathy is a heterogeneous pathological
category including autoantibody-mediated, drug-induced,
paraneoplastic and viral infections [7, 8]. The presence of
anti-SRP antibody is the most frequent etiology. We re-
cently reported that 34 (53 %) of 64 patients with necrotiz-
ing myopathy had anti-SRP antibodies [16]. Anti-HMGCR
and anti-ARS antibodies are also possible candidates as
serological markers of necrotizing myopathy [8]. Anti-
HMGCR antibodies were first known as markers of statin-
induced myotoxocicity; however, they were also found in
patients without statin-exposure [15, 17]. In the present
study, although 5 patients received statins at the disease
onset, they all had anti-SRP antibodies but not anti-
HMGCR antibodies. Moreover, anti-ARS antibodies were
not detected in our 100 patients with anti-SRP antibodies.
The strength of present study is that we screened these 3
autoantibodies using RNA immunoprecipitation and ELI-
SAs. We estimate that 3 types of autoantibodies may be
independently attributed to the immune-mediated patho-
genesis of necrotizing myopathy.
We detected anti-SRP antibodies by 2 different
methods: RNA immunoprecipitation and an SRP54
ELISA. Benveniste et al. developed an addressable laserbead immunoassay using SRP54, and they demonstrated
that the levels of anit-SRP54 antibodies were associated
with the clinical course [12]. However, epitopes of anti-
SRP antibodies are not always located in SRP54. Valiyil
et al. demonstrated that 3 of 8 patients with anti-SRP anti-
bodies did not have the autoantibodies to SRP54 [18]. In
the present study, we have shown that 18 serum samples
with autoantibodies to 7S RNA of SRP were negative for
anti-SRP54 antibodies. It should be emphasized that false-
negative results on an SRP54-specific immunoassay can
be misleading. In contrast, RNA immunoprecipitation can
recognize the conformational epitopes of the SRP com-
plex, although the procedure is technically difficult and
requires some technical skills and cultured cell extracts.
The neurological outcome of the patients with anti-
SRP myopathy was unsatisfactory regardless of the com-
bination of immunosuppressive agents. Our analyses
revealed that pediatric disease onset was the most signifi-
cant factor associated with poor neurological outcomes,
suggesting that the dysfunction of the regeneration
process of muscle fibers may be important in the patho-
genesis of anti-SRP antibodies. In addition, we observed
there was no correlation between the interstitial lung
disease and poor neurological outcome. The severity of
interstitial lung disease seemed to be mild. We thought
decreased capacity of respiratory function was due to
respiratory or trunk muscle weakness. In contrast, the
elevated C-reactive protein was associated with poor
neurological outcome. Increased levels of C-reactive
protein were probably due to the systemic inflammation
of anti-SRP myopathy. However, severe neurological
deficits in SRP-positive patients are not related to
survival.
Other autoantibodies have been found to be closely
associated with the lethal condition, including anti-
melanoma differentiation-associated gene 5 antibodies
with rapidly progressive interstitial lung disease, anti-
transcription intermediary factor 1 antibodies with
malignancy, and anti-mitochondrial antibodies with
cardiac involvement [19–21].
Our study has some limitations. First, the entry of
patients in the present study was based on the referrals
from other institutions. The frequencies of anti-SRP
antibodies were found to be 5 %–8 % of the clinical diag-
noses of myositis. In contrast, the frequency was up to
20 % of patients using the strict criteria of histological
diagnosis [16]. We suspect that the actual prevalence of
anti-SRP antibodies depends on whether the population
is defined by clinical or histological criteria. Second, we
cannot determine the best regimens of immunotherapy
for anti-SRP myopathy. However, we emphasized that our
treatment experience of 100 patients with anti-SRP myop-
athy suggested the valuable information. The combination
of oral corticosteroids and intravenous immunoglobulin
Suzuki et al. Orphanet Journal of Rare Diseases  (2015) 10:61 Page 9 of 9was effective as the first-line therapy. Additional immuno-
suppressive agents were also used for the purpose of redu-
cing side effects of corticosteroids. The removal of anti-
SRP antibodies by plasma exchange was considered as the
second-line therapy.
Conclusion
Anti-SRP antibodies are associated with different clinical
courses and histological presentations. Further studies
should clarify the pathogenesis of anti-SRP antibodies.
Additional file
Additional file 1: Comparison of clinical features between younger
and older onset. Clinical and laboratory characteristic between 13
patients with younger onset and 68 patients with older onset using the
cutoff age of 30 years were compared.
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